Sleep cannabinoids guide: CBN, CBD, melatonin and what the trials measured

CBN has been sold as "the sleep cannabinoid" for a decade. The human evidence is newer and thinner than the marketing, and it is worth reading closely before you build a bedtime routine around a gummy. This guide covers what CBN is, what the two modern trials measured, how it compares with melatonin, what else is in a typical sleep gummy, when to take one, what the law says about THC in a shipped gummy, and why the way CBN is manufactured matters in 2026.

Why is CBN called the sleep cannabinoid?

The story behind the name is chemistry. CBN is not made by the hemp plant directly. It "is a degradative product of delta-9-tetrahydrocannabinol," and "CBN levels increase over time as THC is exposed to light, oxygen, and heat" (Corroon, 2021). Old, poorly stored cannabis has more CBN than fresh cannabis, and old cannabis has a reputation for producing drowsiness, so CBN inherited the reputation. That is association, not a controlled result.

The review's author searched the literature from 1945 to January 2021, screened 99 human studies, and extracted 8 that met inclusion criteria. Those 8 were small, with most groups under 60 participants, and the author describes them as having "small sample sizes lacking diversity in sociodemographic characteristics" (Corroon, 2021). Several tested CBN together with THC, which makes it impossible to separate the two.

Montana's cannabis regulator, in a January 2025 bulletin, summarizes the consumer side neutrally: CBN "is generally considered non-intoxicating," some users "report a calming effect that leads to drowsiness," and "CBN is typically marketed as a sleep aid" (Montana Cannabis Control Division). Marketed as is the accurate verb. The next section covers what has actually been measured.

What did the CBN human trials actually measure?

That trial, run between May and November 2022 by employees of a cannabis producer, randomized adults aged 18 to 55 to placebo, 20 mg CBN alone, or 20 mg CBN with 10, 20 or 100 mg of CBD. The primary endpoint was self-rated sleep quality. The odds ratio for 20 mg CBN alone was 2.26 with a confidence interval of 0.93 to 5.52, which the authors describe as "a nonsignificant but potentially meaningful effect on sleep quality" (Bonn-Miller et al., 2024). There was no difference from placebo for time to fall asleep, time awake after sleep onset, or daytime fatigue, and adding CBD "did not positively augment" the CBN effect.

The second trial is larger and reaches a different conclusion about CBN. It randomized 1,793 adults with disturbed sleep to 4 weeks of capsules containing 15 mg CBD or 5 mg melatonin, alone or with 15 mg CBN and 5 mg CBC. All arms improved against their own baseline, 56% to 75% of participants reported a clinically important improvement, but there were "no significant differences in effect" between 15 mg CBD alone and the arms that added 15 mg CBN (Saleska et al., 2023). The authors conclude that adding low doses of CBN and CBC "may not improve the effect" of CBD or melatonin on their own.

Read together: one 7-night trial found a modest signal for 20 mg of CBN on awakenings; one 4-week trial found that 15 mg of CBN added nothing measurable to 15 mg of CBD or 5 mg of melatonin. Neither used sleep-lab recordings; both relied on questionnaires. Both were funded or run by companies with products to sell. That is the full human evidence base for CBN and sleep as of 2026.

CBN vs melatonin: how do they differ?

Melatonin has a far larger evidence base and a far larger user base. Adult use in the United States rose from 0.4% in 1999 to 2000 to 2.1% in 2017 to 2018 in a national survey of 55,021 adults, and the share taking more than 5 mg per day rose from 0.08% to 0.28% (Li et al., 2022). NCCIH's summary is that "Short-term use of melatonin supplements appears to be safe for most people" and that long-term data are lacking (NCCIH).

The two compounds also differ in how reliably they are dosed. A 2023 JAMA analysis of 25 melatonin gummy products found actual melatonin content ranging from 74% to 347% of the label, with only 3 of 25 (12%) within 10% of the declared amount; 5 products that also declared CBD measured 104% to 118% of label for CBD (Cohen et al., 2023). NCCIH cites the same study: "22 out of 25 over-the-counter melatonin gummy products were inaccurately labeled" (NCCIH). The CBD numbers in that study were tighter than the melatonin numbers.

The practical difference is timing and role. Melatonin is a darkness signal, which is why the trial NCCIH describes gave it 1 hour before the desired bedtime alongside a fixed bedtime (NCCIH). CBN has no such biological role; the 20 mg trial simply dosed it nightly for a week (Bonn-Miller et al., 2024). If you are choosing between them, the honest summary is that melatonin has decades of data and a known mechanism, and CBN has two trials and a story.

What is in a sleep gummy (CBD, CBN, melatonin, L-theanine)?

CBD is the base of most sleep gummies and the ingredient with the most human data. Its pharmacokinetics are slow: the prescription label reports a time to peak of 2.5 to 5 hours and a half-life of 56 to 61 hours after a week of twice-daily dosing (FDA prescribing information). A gummy taken at bedtime is still rising in the blood when you fall asleep, and daily use accumulates over the first week.

CBN is the marketing ingredient. Typical gummies carry 5 to 20 mg, bracketing the 15 mg and 20 mg amounts in the two trials above. Melatonin, when present, is usually 1 to 5 mg; the 5 mg arm in the comparison trial performed as well as any cannabinoid arm (Saleska et al., 2023). Given the label-accuracy data on melatonin gummies, a certificate of analysis that reports the melatonin number, not only the cannabinoids, is worth asking for.

L-theanine is an amino acid from tea. In a 4-week crossover trial of 30 healthy adults, 200 mg nightly before sleep lowered a standard sleep-quality questionnaire score from 9.67 to 8.3 within the L-theanine period (p = 0.013), but the between-group difference against placebo did not reach significance (p = 0.073) (Hidese et al., 2019). That is a modest, mixed result at 200 mg; many gummies contain far less. Read the label for each active, add up the milligrams, and compare them with the trial amounts before assuming the blend does anything the single ingredients do not.

When should you take a sleep gummy?

Consistency matters more than the exact hour because of accumulation. With a half-life of roughly 2.5 days, a nightly gummy builds toward a steady level over the first week (FDA prescribing information). Judging a sleep gummy on night one is judging it before it has reached the level it will hold on night seven. The 7-night CBN trial and the 4-week comparison trial both measured outcomes over days and weeks, not single nights (Bonn-Miller et al., 2024; Saleska et al., 2023).

Food changes the number. The prescription label reports a 5-fold increase in peak concentration and a 4-fold increase in total exposure when CBD was taken with a high-fat, high-calorie meal rather than fasted (FDA prescribing information). A gummy after dinner and a gummy on an empty stomach at midnight are different servings. Pick one pattern and keep it for the whole two weeks you are evaluating.

Pair the gummy with the behaviors that have the strongest evidence. CDC's sleep guidance for adults 18 to 60 is 7 or more hours, and its habit list includes "Going to bed and getting up at the same time every day" and "Turning off electronic devices at least 30 minutes before bedtime" (CDC). A gummy taken at a fixed time becomes an anchor for the fixed bedtime, which is the part that does the work.

What does the research say about CBD and sleep?

The sleep-lab study is the most rigorous and the most sobering. Twenty-six healthy volunteers received 300 mg of CBD or placebo on two nights, 30 minutes before an 8-hour polysomnography recording. No polysomnographic parameter differed between conditions; total sleep time was 389.3 minutes with placebo and 388.1 minutes with CBD, and morning cognitive and motor tests were unchanged. The authors concluded that CBD "does not appear to interfere with the sleep cycle" of healthy people (Linares et al., 2018). The same result means it did not improve it either, in people whose sleep was already normal.

The most-cited positive paper is a chart review, not a trial. Clinicians at one practice reviewed 103 adult charts and reported on 72; sleep scores improved within the first month in 48 of them (66.7%) "but fluctuated over time," and CBD was described as well tolerated in all but 3 (Shannon et al., 2019). With no control group and self-selected patients, this is a reason to run trials, which is the authors' own conclusion, rather than evidence that CBD does anything on its own.

NCCIH's standing summary is that the effects of cannabis and cannabinoids on sleep in otherwise healthy people are uncertain (NCCIH). The honest reading of the 2018 to 2024 literature is this: low-dose CBD is well tolerated over weeks, people who take it in trials report better sleep than they reported at baseline, a 5 mg melatonin capsule produced the same report, and an objective sleep lab saw nothing at 300 mg in healthy sleepers. Use it as part of a routine, not as the routine.

Are sleep gummies with THC legal to ship?

The 0.3% figure is the current federal line between hemp and marijuana, measured on a dry-weight basis in the statute (7 U.S.C. 1639o). A gummy that stays under 0.3% THC by weight can still contain several milligrams of THC per piece, which is why "hemp-derived THC gummies" exist at all. That loophole is what the 2025 amendment closes.

Public Law 119-37, section 781, rewrote the hemp definition to use "a total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid) of not more than 0.3 percent," and to exclude final products with "greater than 0.4 milligrams combined total per container" of THC and related cannabinoids, along with cannabinoids "synthesized or manufactured outside the plant" (7 U.S.C. 1639o, amendment notes). The amendment was scheduled to take effect 365 days after the November 12, 2025 enactment.

Congress then split the start date. Public Law 119-103, approved September 2, 2026, provides that "Until December 11, 2026," the section 781 amendments apply only to the paragraphs covering cannabinoids the plant cannot naturally produce (Public Law 119-103, Sec. 2019). Everything else, including the 0.4 mg per-container cap, lands on December 11, 2026. After that date a sleep gummy with any meaningful THC content stops being hemp under federal law, carriers' hemp policies stop covering it, and a container with 0.4 mg or less of total THC is the only federally shippable form. State rules layer on top of that and vary; check the state matrix before shipping to any address.

How do you build a sleep routine around a cannabinoid?

A routine that works has a fixed wake time, a fixed wind-down start, and a fixed gummy time inside the wind-down. CDC's list adds "Keeping your bedroom quiet, relaxing, and at a cool temperature," "Avoiding caffeine in the afternoon or evening," and "Avoiding large meals and alcohol before bedtime" (CDC). Those behaviors have more evidence behind them than any cannabinoid, and a gummy cannot compensate for a bedtime that moves two hours between weekdays and weekends.

Give the routine two weeks and keep a log. The 7-night CBN trial and the 4-week comparison trial both scored sleep with questionnaires over days to weeks (Bonn-Miller et al., 2024; Saleska et al., 2023). Score your own sleep each morning on a 1 to 5 scale before you do anything else, and write down the gummy time and whether you ate with it. After 14 days, compare the second week with the first and with the week before you started.

Keep the milligrams modest and steady. The trials used 15 to 20 mg of CBN and 15 mg of CBD; more is not better by any published measure, and the common unwanted effects of larger cannabinoid servings are daytime sleepiness and digestive upset. If the log shows morning grogginess, move the gummy earlier or cut it in half rather than adding a second one. And keep the melatonin honest: given that 22 of 25 melatonin gummies were mislabeled in the JAMA sample (Cohen et al., 2023), a product that publishes a lab-tested melatonin number is worth more than one with a bigger number on the front.

How is CBN made (natural degradation vs conversion) and why does that matter in 2026?

The plant makes very little CBN on its own. It is "a degradation product of Δ9-THC" and "may be found at elevated levels in biomass that has been stored in poor conditions for extended periods of time" (Montana Cannabis Control Division). Because hemp contains almost no THC to begin with, there is almost no natural CBN to extract from it. The regulator is blunt about the consequence: "any hemp derived CBN (distillate or isolate) is typically chemically synthesized from CBD to be financially profitable."

That matters for quality. The Montana bulletin notes that synthetically derived cannabinoids "use toxic diluents, dangerous reagents," and that an isolate "may be concentrated, but still retain cannabinoid isomers, residual solvents, and other reagents" (Montana Cannabis Control Division). Its most useful sentence for a buyer is that a manufacturer's COA "does not adequately demonstrate the synthetic or non-synthetic status of CBN," because a potency test shows what is in the bottle, not how it was made. Montana prohibited sales of synthetically derived cannabinoids on May 22, 2023.

That matters for legality in 2026 because the federal hemp definition now excludes cannabinoids that "were synthesized or manufactured outside the plant," with that clause effective December 11, 2026 under the latest extension (7 U.S.C. 1639o; Public Law 119-103). The statute also directed FDA to publish lists of cannabinoids the plant naturally produces; TODO: verify whether FDA has published those lists before updating this page. Until then, the question to put to any CBN supplier is not "what is the potency" but "what was the process," in writing, for every lot.

This page is general information, not personalized guidance. FDA has not evaluated these statements.